Cardiovascular Disease

Organon has partnered with Daiichi Sankyo Europe to distribute Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland, and Norway. This collaboration aims to increase patient access to Nilemdo®, a novel treatment for high cholesterol and cardiovascular disease risk, especially for those intolerant to statins. Organon will handle distribution and promotion, supporting its cardiovascular portfolio and addressing unmet patient needs, particularly for women who often experience statin intolerance.

Eli Lilly will acquire Verve Therapeutics, a clinical-stage company focused on gene editing therapies for cardiovascular disease. The deal, valued at approximately $1 billion, aims to advance Verve’s one-time treatment approach targeting genes linked to heart disease. Lilly plans to leverage its expertise in cardiometabolic diseases and gene medicines to develop Verve’s pipeline, including VERVE-102.